Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients

Ain Shams University60 enrolled

Overview

The work aimed to compare the effects of Sodium-glucose co-transporter-2 (SGLT2) inhibitors on glomerular filtration rate (GFR) in patients with diabetic chronic kidney disease (CKD) and non-diabetic CKD.

Glucose reabsorption is mediated by the sodium-glucose cotransporter (SGLT) 2, which reabsorbs 90% of glucose, and SGLT1, which reabsorbs the remaining 10%. The relationship between hyperglycaemia and the development of renal disease is complex. Hyperglycaemia-induced complications are mediated by several metabolic pathways, among which accumulation of Advanced Glycation End-products with abnormalities of the glycosylation of macromolecules and increased glucose flux through the polyol pathway seem to be the most important.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Sodium Glucose Co-Transporter 2 Inhibitors Estimated Glomerular Filtration Rate Diabetes Chronic Kidney Disease

Interventions

Sodium Glucose Co-Transporter 2 InhibitorsOTHER

All candidates start therapy with sodium glucose co-transporter 2 (SGLT2) inhibitors with a dose of 10mg daily Dapagliflozin for 6 months

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥ 18 years. * Both sexes. * Chronic kidney disease (CKD) participants with stages 3 and 4. Exclusion Criteria: * Patients with type 1 diabetes mellitus (DM). * Patients with decompensated Chronic liver disease. * Patients with uncontrolled hypertension. * Patients with blood pressure (BP) \> 110/70. * Patients already on the same medication (Sodium Glucose Co-Transporter 2 Inhibitors). * Patients with a history of recurrent or recent urinary tract infection (UTI). * Patients with glycated hemoglobin (HbA1c) ≤10. * Adult polycystic kidney disease. * All patients on immunosuppressive medications.

Locations (1)

Ain Shams University

Cairo, Egypt

Outcomes

Primary Outcomes

Change in the estimated glomerular filtration rate

Change in the estimated glomerular filtration rate (eGFR) was recorded.

Time frame: 6 months post-procedure

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.